T1	Participants 105 124	stage III melanoma.
T2	Participants 250 292	stage III (regional lymph nodes) melanoma.
T3	Participants 320 362	patients without any detectable metastases
T4	Participants 547 633	Eighty-eight patients determined as eligible for treatment were enrolled in the study.
